LC-FACSeq is a method for detecting rare clones in leukemia.
Clonal selection
Diagnostics
Genetics
Leukemias
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
18 06 2020
18 06 2020
Historique:
received:
15
11
2019
accepted:
06
05
2020
entrez:
20
6
2020
pubmed:
20
6
2020
medline:
9
6
2021
Statut:
epublish
Résumé
Detecting, characterizing, and monitoring rare populations of cells can increase testing sensitivity, give insight into disease mechanism, and inform clinical decision making. One area that can benefit from increased resolution is management of cancers in clinical remission but with measurable residual disease (MRD) by multicolor FACS. Detecting and monitoring genomic clonal resistance to treatment in the setting of MRD is technically difficult and resource intensive due to the limited amounts of disease cells. Here, we describe limited-cell FACS sequencing (LC-FACSeq), a reproducible, highly sensitive method of characterizing clonal evolution in rare cells relevant to different types of acute and chronic leukemias. We demonstrate the utility of LC-FACSeq for broad multigene gene panels and its application for monitoring sequential acquisition of mutations conferring therapy resistance and clonal evolution in long-term ibrutinib treatment of patients with chronic lymphocytic leukemia. This technique is generalizable for monitoring of other blood and marrow infiltrating cancers.
Identifiants
pubmed: 32554930
pii: 134973
doi: 10.1172/jci.insight.134973
pmc: PMC7406301
doi:
pii:
Substances chimiques
Piperidines
0
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : F30 CA225070
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA177292
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197734
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233338
Pays : United States
Références
Ann Oncol. 2018 Jan 1;29(suppl_1):i10-i19
pubmed: 29462254
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Blood. 2018 Apr 26;131(17):1910-1919
pubmed: 29437592
Blood. 2018 Oct 11;132(15):1568-1572
pubmed: 30111609
Leukemia. 2003 Jun;17(6):1013-34
pubmed: 12764363
N Engl J Med. 2013 Jul 4;369(1):32-42
pubmed: 23782158
Nature. 2015 Oct 22;526(7574):525-30
pubmed: 26466571
Leukemia. 2017 Jul;31(7):1645-1647
pubmed: 28366935
Nature. 2011 Jun 05;475(7354):101-5
pubmed: 21642962
Blood Adv. 2017 May 02;1(12):715-727
pubmed: 29296715
Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5
pubmed: 24234437
Blood. 2011 Jun 9;117(23):6287-96
pubmed: 21422473
Nature. 2015 Oct 22;526(7574):519-24
pubmed: 26200345
N Engl J Med. 2014 Jun 12;370(24):2286-94
pubmed: 24869598
Blood. 2018 May 24;131(21):2357-2366
pubmed: 29483101
N Engl J Med. 2018 Dec 27;379(26):2517-2528
pubmed: 30501481
Haematologica. 2010 Sep;95(9):1526-33
pubmed: 20421272
Nat Commun. 2016 May 20;7:11589
pubmed: 27199251
Nat Commun. 2017 Dec 19;8(1):2185
pubmed: 29259203
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):173-8
pubmed: 24347635
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
Blood. 2015 Mar 26;125(13):2062-7
pubmed: 25573991
JAMA Oncol. 2015 Apr;1(1):80-7
pubmed: 26182309
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Blood. 2014 Feb 20;123(8):1207-13
pubmed: 24311722
J Mol Diagn. 2015 Nov;17(6):652-60
pubmed: 26319783
N Engl J Med. 2018 Sep 13;379(11):1028-1041
pubmed: 30207916
Cell. 2013 Feb 14;152(4):714-26
pubmed: 23415222